

Quarterly Activities Report and Appendix 4C


HIGHLIGHTS

- Quarterly sales of \$4.4 million, in line with the prior corresponding period reflecting higher testing rates typically experienced during the Australian winter respiratory season;
- Organisational changes implemented during the quarter, including changes to US leadership and focused reorganisation of US team to better align with current strategy and needs;
- Ramp-up of US sales have been impacted by prospective customers' internal processes, competing priorities, preference for enhanced workflow and uncertainty in the US healthcare environment. Subsequent to quarter end an additional US contract was signed with an integrated health care organisation;
- Development of automated, high-throughput solution through customisation of commercially available instruments commenced with establishment of strategic three-way partnership;
- Strong engagement with molecular experts globally, with relevant key opinion leaders presenting at leading European conference to showcase the benefits of the Company's molecular diagnostic solutions; *and*
- Strong balance sheet with \$30.9 million cash balance at 30 June 2025.

Operational and Trading Update

In Q4 FY2025, the Company recorded sales of \$4.4 million (unaudited), an increase of 52% from the preceding quarter and in line with the prior corresponding period (p.c.p.) reflecting higher testing rates typically experienced during the Australian winter respiratory season.

Figure 1: GSS Quarterly revenue (A\$m)



Receipts from customers for the quarter were \$3.6 million, an 67.5% increase on the p.c.p. Strong cash receipts were primarily attributable to Australian sales which benefitted from seasonally higher respiratory testing rates in Australia. The net operating cash outflow for the quarter was \$5.9 million, reflecting higher investment in inventory for the Australian winter respiratory season.

Net investing cash outflows of \$0.2 million for the quarter included investments in equipment for placement at customers and within the Company's R&D laboratories. Payments of fees to Directors, including the CEO, were \$0.3 million for the quarter and are included in 1.2(e) – staff costs of the Appendix 4C.

Restructured organisation aligned with priorities

During the quarter, the Company conducted a review of its organisational structure to assess where resources should be best placed to achieve the company's priorities. As a result of this evaluation, selective redundancies were implemented, alongside targeted investments in areas requiring specialised expertise to support key priorities in the years ahead.

The main aim of this process has been to sharpen the focus across the core business pillars while ensuring operating expenses are effectively managed as the Company prepares for future sales growth. As part of the broader evaluation, the Company has undertaken a strategic refresh of its purpose, mission, and values, with updated principles introduced on 1 July 2025 to better align with long-term objectives.

Progress in the United States

While the sales cycle is taking longer than previously communicated, we remain confident in the US opportunity. To realise opportunities faster, we have made significant changes to the US leadership and team, and the US go to market strategy, including channels, target decision makers and increasing product awareness.

The US team is now led by Sarah Peaty, who has previously held senior roles in molecular diagnostic sales with Roche Diagnostics and Hologic Inc. In addition, Allison Rossiter continues to have direct engagement with all key potential opportunities.

Being successful in the US involves a wide range of stakeholders, that have not, until now, been a key focus. The newly launched go to market strategy reflects all aspects of the patient and clinical pathways and covers a wider range of influencers and decision makers, from patients through to clinicians, as well as laboratory personnel and hospital leadership.

Genetic Signatures continues to move prospective customers through the sales pipeline, including ongoing engagement with all the large commercial reference laboratories in the US. The conversion of these opportunities into revenue-generating contracts is taking longer than anticipated, primarily due to internal processes and competing priorities within customer organisations. In addition, the volatility in the current US macro environment has had a negative impact on decision making for these customers.

Some higher throughput laboratories have shown interest in the *EasyScreen*TM Gastrointestinal Parasite Detection Kit but have indicated a preference for greater automation with the workflow. The commercial team are engaging with these laboratories to better understand their needs, while our technical teams explore opportunities to enhance the workflow experience and streamline the overall process in the short term. In the longer term, the new automated instrument will enhance our solution globally.

In the previous quarter, the Company secured its first commercial agreement for the *EasyScreen*TM Gastrointestinal Parasite Detection Kit. This customer was not part of the initial customer experience program and therefore needed to complete internal validation of our molecular test kit and workflow during the quarter. That validation process is now complete, and we anticipate revenue generation from this customer during FY 2026.

Since the close of the quarter, an additional US contract has been signed, a former 'customer experience' site. This customer is one of the largest nonprofit integrated health care systems in the United States. The laboratory will be performing tests on behalf of the 56 hospitals which are in the Group. We anticipate revenue in year 1 to be immaterial, but expect revenues to increase throughout the life of the contract.

Commercial sales progress in EMEA

As part of the strategic review that took place during the quarter, the EMEA team and product offering were consolidated. This initiative aims to sharpen focus on high-impact geographies and optimise return on investment, prior to any future expansion.

Positive progress has been observed in the United Kingdom, where several National Health Service trusts are successfully utilising Genetic Signatures' enteric viral, bacteria and parasite test kits in hospital settings. These tests have proven effective in supporting infection control measures by screening for

highly contagious pathogens, thereby helping to prevent outbreaks that can result in the closure of high-demand hospital wards.

In addition, the region continues to assess distribution opportunities, particularly in markets where local representation is essential due to language and cultural considerations, and where direct sales operations may not be economically viable.

Strong engagement with molecular experts globally

Genetic Signatures actively participated in leading conferences across Europe and the United States to raise awareness of its molecular diagnostic technologies. At the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) conference in Vienna in April 2025, Dr. Susan Antenucci from the Wadsworth Centre presented findings on the Company's *EasyScreen*™ Gastrointestinal Parasite Detection Kit, highlighting its performance compared to laboratory-developed tests. The conference also saw, Elisabetta Savanco from Blackpool Teaching Hospital in the UK sharing insights on implementing a pan-enteric PCR screening approach in a general district hospital setting. The presentations from key opinion leaders of their experiences on our behalf is a key pillar of our engagement with prospective customers in the pipeline.

In June 2025, Genetic Signatures also showcased the *EasyScreen*™ Gastrointestinal Parasite Detection Kit at the American Society for Microbiology Conference, engaging with key laboratory personnel, and further promoting the technology within the microbiology community.

Three-way partnership for new instruments and software

The Genetic Signatures R&D team remains focused on enhancing existing workflows for current customers, with an emphasis on increasing automation and improving the usability of the current instrumentation, while new hardware and software solutions are being developed.

In February 2025, Genetic Signatures announced that it has established a new strategy for developing automated, high-throughput solutions, through the customisation of commercially available instruments. During the current quarter, the Company partnered with Tecan Group to customise a commercially available instrument to enhance automation and provide ease of use for customers. The Company also engaged Repado to develop the software and a next-generation results analysis platform for streamlined patient sample reporting.

The first phase of this project has commenced and includes the finalisation of detailed scope of works which will lead into a second phase where the integrated customisation of both hardware and software will be undertaken.

Genetic Signatures has also initiated a comprehensive market assessment to support the expansion of its **3base**® technology syndromic infectious disease menu, which will be launched alongside the new integrated hardware and software solution.

Improving supply chain resilience for key manufacturing components

Investments have been made in research, development and procurement to reduce risk and to strengthen the supply of key manufacturing components. The project is in progress, and the current initiative remains on schedule.

Outlook

As of 30 June 2025, Genetic Signatures held a cash balance of \$30.9 million. Looking ahead, the Company remains committed to maintaining and growing the footprint in Australia, while expanding market presence globally, with a particular focus on the United States and the United Kingdom. This strong cash position provides the resources to continue supporting our team and commercial initiatives, while also driving innovation across assay development, workflow optimisation, instrumentation, and software enhancements.

– END –

Announcement authorised by Genetic Signatures' Board of Directors

For further information, see our website (www.geneticsignatures.com) or contact us:

Allison Rossiter

Chief Executive Officer

allison.rossiter@geneticsignatures.com

T: +61 (0)2 9870 7580

Karl Pechmann

Chief Financial Officer

karl.pechmann@geneticsignatures.com

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base®**. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen™* brand. Genetic Signatures' proprietary MDx **3base®** platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospital and pathology laboratories undertaking infectious disease screening.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

GENETIC SIGNATURES LIMITED

ABN

30 095 913 205

Quarter ended ("current quarter")

30 June 2025

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	3,609	18,168
1.2 Payments for		
(a) research and development	(569)	(2,102)
(b) product manufacturing and operating costs	(4,124)	(11,363)
(c) advertising and marketing	(569)	(1,361)
(d) leased assets	(41)	(349)
(e) staff costs	(3,042)	(16,788)
(f) administration, corporate and other costs	(1,549)	(4,636)
1.3 Dividends received (see note 3)		
1.4 Interest received	347	1,231
1.5 Interest and other costs of finance paid	(14)	(91)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	5,002
1.8 Other (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	(5,952)	(12,289)

2. Cash flows from investing activities		
2.1 Payments to acquire:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	(211)	(653)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
	(d) investments	-	-
	(e) intellectual property	-	(249)
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(211)	(902)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	8,632
3.2	Proceeds from issue of convertible debt securities		
3.3	Proceeds from exercise of options	-	137
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	(554)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Principal element of lease payments	(115)	(429)
3.10	Net cash from / (used in) financing activities	(115)	7,785

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	37,158	36,252
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(5,952)	(12,289)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(211)	(902)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(115)	7,785
4.5	Effect of movement in exchange rates on cash held	(7)	27
4.6	Cash and cash equivalents at end of period	30,873	30,873

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	7,473	8,758
5.2	Call deposits	23,400	28,400
5.3	Bank overdrafts		
5.4	Other (provide details)		
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	30,873	37,158

6. Payments to related parties of the entity and their associates

- 6.1 Aggregate amount of payments to related parties and their associates included in item 1
- 6.2 Aggregate amount of payments to related parties and their associates included in item 2

**Current quarter
\$A'000**

275

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments

7. Financing facilities

Note: the term "facility" includes all forms of financing arrangements available to the entity.

Add notes as necessary for an understanding of the sources of finance available to the entity.

7.1 Loan facilities

7.2 Credit standby arrangements

7.3 Other (please specify)

7.4 **Total financing facilities**

Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000

7.5 **Unused financing facilities available at quarter end**

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8. Estimated cash available for future operating activities**\$A'000**

8.1	Net cash from / (used in) operating activities (Item 1.9)	(5,952)
8.2	Cash and cash equivalents at quarter end (Item 4.6)	30,873
8.3	Unused finance facilities available at quarter end (Item 7.5)	-
8.4	Total available funding (Item 8.2 + Item 8.3)	30,873
8.5	Estimated quarters of funding available (Item 8.4 divided by Item 8.1)	5.18

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

1. Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer:

2. Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:

3. Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 22 July 2025

Authorised by: Board of Directors

(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.